Teva announced last week that its CEO, Jeremy Levin, is to resign with immediate effect. This reportedly follows disagreements with the Teva Board over the implementation of the company’s strategy, as well as a slating from analysts and investors. Employees are also unhappy, after...
Here we go again: Pfizer sets up a new generics division
On July 29th, Pfizer announced that it would follow the lead set by GSK three months previously and divide up its business so as to create a separate unit containing its off-patent (i.e. generic) products. The new division, which is described as the Value...
Pharmstandard’s plans show that not all shareholders are equal
It is always nice to have prejudices vindicated and this week, Pharmstandard delivered a truly impressive illustration of the dangers of doing business in Russia, particularly if you are the minority shareholder of a quoted company. Information about exactly what is going on has...
Introspection in Athens: Thoughts from the EGA meeting 2013
It is perhaps appropriate that the EGA (European Generics Association) met this year in Athens, cradle of philosophy, as the organisation appears to be undergoing something of an existential crisis. With an increasing number of its members turning their backs on generics as the...
A, you’re adorable: suddenly Actavis is everybody’s favourite
Actavis appears to be in the centre of a social whirl, with reports emerging that it has been considering a takeover approach from Valeant, a merger offer from Mylan and the purchase of Warner Chilcott*. The first two appear to be connected, with Mylan...
Hikma’s strategy in the balance as it considers strategic options
Hikma’s FY 2012 results, which were out yesterday, made no direct mention of the company’s announcement on March 1st that it might sell its injectables business, but nevertheless provided considerable food for thought about Hikma’s future strategic direction. Analyst interest focused mainly on the...
Actavis shows its feminine side with purchase of Uteron
Actavis (née Watson) announced on Wednesday that it will spend up to $305m, including a $150m up-front payment and a potential $45m in near-term milestones for Uteron, a private Belgian company specialised in developing women’s health products. The co-founders of Uteron, one of whom...